Nurix Therapeutics Quarterly Cash Flow Statement
NASDAQ: NRIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nurix Therapeutics free cash flow
In the quarter ended May 31, 2026, Nurix Therapeutics generated -$96.6 million of operating cash flow and spent $1.9 million on capital expenditures. That left free cash flow of -$98.5 million, a free-cash-flow margin of -1089.3% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Nurix Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-05-31 | Q1 20262026-02-28 | Q4 20252025-11-30 | Q3 20252025-08-31 | Q2 20252025-05-31 | Q1 20252025-02-28 | Q4 20242024-11-30 | Q3 20242024-08-31 | Q2 20242024-05-31 | Q1 20242024-02-29 | Q4 20232023-11-30 | Q3 20232023-08-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -89.53M | -87.17M | -78.22M | -86.42M | -43.46M | -56.35M | -58.55M | -48.96M | -44.55M | -41.52M | -41.96M | -36.98M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 2.25M | 2.20M | 2.12M | 2.03M | 2.24M | 2.35M | 2.55M | 2.39M | 2.33M | 2.04M | 1.93M | 1.95M |
| Stock-Based Compensation | 11.39M | 9.40M | 9.09M | 9.77M | 10.38M | 8.72M | 8.51M | 8.75M | 8.85M | 7.82M | 8.02M | 8.45M |
| Change in Working Capital | -4.91M | -426.00K | -11.84M | -7.64M | -5.07M | -19.29M | -6.92M | -7.06M | 2.54M | -12.35M | 57.07M | -17.62M |
| Operating Cash Flow | -96.57M | -71.91M | -67.83M | -57.38M | -63.16M | -61.09M | -48.75M | -42.18M | -39.70M | -41.95M | 26.69M | -41.13M |
| Capital Expenditures | -1.94M | -1.04M | -5.13M | -2.71M | -2.67M | -3.48M | -2.10M | -2.35M | -1.94M | -2.88M | -2.58M | -2.46M |
| Investing Cash Flow | 93.00M | -123.83M | 346.00K | 50.48M | 71.50M | 25.53M | -140.82M | -21.34M | -131.07M | 35.51M | -14.37M | 22.77M |
| Financing Cash Flow | 66.00K | 19.98M | 236.01M | 1.16M | 6.00K | 1.47M | 200.52M | 45.77M | 237.75M | 1.62M | 7.00K | 1.70M |
| Net Change in Cash | -3.51M | -175.76M | 168.52M | -5.75M | 8.34M | -34.08M | 10.95M | -17.75M | 66.98M | -4.81M | 12.32M | -16.65M |
| Free Cash Flow | -98.51M | -72.96M | -72.96M | -60.10M | -65.84M | -64.57M | -50.86M | -44.52M | -41.64M | -44.84M | 24.10M | -43.59M |
This table shows 12 quarterly periods of Nurix Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NRIX's reporting calendar. What is a cash flow statement?